The mTOR inhibitor RAPA is used in transplant patients to prevent allograft rejection; however, as discussed earlier, prolonged RAPA treatment can promote Akt activation through the withdrawal of negative feedback loop, and thus can facilitate tumor growth [17]. The gene discussed is AKT1; the disease is neoplasm.